As of 2024-12-11, the Relative Valuation of Kalvista Pharmaceuticals Inc (KALV) is (34.30) USD. This relative valuation is based on P/E multiples. With the latest stock price at 9.44 USD, the upside of Kalvista Pharmaceuticals Inc based on Relative Valuation is -463.4%.
The range of the Relative Valuation is (14.73) - (53.15) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 5.1x - 18.4x | 11.8x |
| Forward P/E multiples | 5.1x - 18.9x | 12.0x |
| Fair Price | (14.73) - (53.15) | (34.30) |
| Upside | -256.1% - -663.0% | -463.4% |
| Date | P/E |
| 2024-12-03 | -3.40 |
| 2024-12-02 | -3.56 |
| 2024-11-29 | -3.48 |
| 2024-11-27 | -3.49 |
| 2024-11-26 | -3.46 |
| 2024-11-25 | -3.49 |
| 2024-11-22 | -3.51 |
| 2024-11-21 | -3.23 |
| 2024-11-20 | -3.10 |
| 2024-11-19 | -3.13 |
| 2024-11-18 | -3.22 |
| 2024-11-15 | -3.29 |
| 2024-11-14 | -3.39 |
| 2024-11-13 | -3.62 |
| 2024-11-12 | -3.69 |
| 2024-11-11 | -3.84 |
| 2024-11-08 | -3.95 |
| 2024-11-07 | -3.87 |
| 2024-11-06 | -3.95 |
| 2024-11-05 | -3.89 |
| 2024-11-04 | -4.03 |
| 2024-11-01 | -3.67 |
| 2024-10-31 | -3.56 |
| 2024-10-30 | -3.88 |
| 2024-10-29 | -4.08 |
| 2024-10-28 | -4.19 |
| 2024-10-25 | -4.04 |
| 2024-10-24 | -4.18 |
| 2024-10-23 | -4.16 |
| 2024-10-22 | -4.28 |
| 2024-10-21 | -4.27 |
| 2024-10-18 | -4.33 |
| 2024-10-17 | -4.19 |
| 2024-10-16 | -4.27 |
| 2024-10-15 | -4.15 |
| 2024-10-14 | -4.06 |
| 2024-10-11 | -4.03 |
| 2024-10-10 | -3.80 |
| 2024-10-09 | -3.89 |
| 2024-10-08 | -3.88 |
| 2024-10-07 | -3.91 |
| 2024-10-04 | -3.93 |
| 2024-10-03 | -4.00 |
| 2024-10-02 | -4.10 |
| 2024-10-01 | -3.94 |
| 2024-09-30 | -4.01 |
| 2024-09-27 | -4.27 |
| 2024-09-26 | -3.46 |
| 2024-09-25 | -3.28 |
| 2024-09-24 | -3.34 |